Spots Global Cancer Trial Database for melanoma stage iii
Every month we try and update this database with for melanoma stage iii cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma | NCT03153085 | Melanoma Stage ... Melanoma Stage ... | TBI-1401(HF10) Ipilimumab | 20 Years - | Takara Bio Inc. | |
| The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma | NCT05827770 | Melanoma Stage ... | Toripalimab com... | 18 Years - 80 Years | Fudan University | |
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | NCT04598009 | Melanoma Stage ... Melanoma Stage ... | Binimetinib Imatinib | 18 Years - | University of California, San Francisco | |
| Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | NCT05652673 | Melanoma Stage ... Melanoma Stage ... Immunotherapy Toxicity, Drug | nivolumab | 18 Years - | Erasmus Medical Center | |
| Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT) | NCT05445752 | Melanoma Stage ... | 18 Years - 90 Years | Hospital Universitario Virgen Macarena | ||
| Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG | NCT05467137 | Melanoma, Stage... Melanoma, Stage... Melanoma Stage ... | MSOT | 18 Years - | University Medical Center Groningen | |
| The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma | NCT05827770 | Melanoma Stage ... | Toripalimab com... | 18 Years - 80 Years | Fudan University | |
| SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study) | NCT04079166 | Malignant Melan... Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... | SCIB1 DNA vacci... | 18 Years - | Scancell Ltd | |
| CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | NCT05289193 | Melanoma Melanoma Stage ... | PET Scan Nivolumab Ipilimumab Surgical Resect... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | NCT04562129 | Melanoma Stage ... Melanoma Stage ... Inoperable Dise... | Interleukin-2 Ipilimumab Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain | NCT03605771 | Melanoma Stage ... Melanoma Stage ... Advanced Cancer | Daily Clinical ... | 18 Years - | Grupo Español Multidisciplinar de Melanoma | |
| MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns] | NCT06299878 | Melanoma, Skin Melanoma Stage ... | Gut microbiota ... | 18 Years - | Russian Academy of Medical Sciences | |
| IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | NCT04562129 | Melanoma Stage ... Melanoma Stage ... Inoperable Dise... | Interleukin-2 Ipilimumab Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma | NCT05732805 | Melanoma Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... Melanoma Unrese... Melanoma Metast... Melanoma Advanc... | BCD-217 BCD-100 Placebo | 18 Years - | Biocad | |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | NCT05970497 | Cancer Melanoma Stage ... Melanoma Stage ... Cutaneous Melan... Osteosarcoma Carcinoma, Squa... Carcinoma, Basa... | KB707 | 18 Years - | Krystal Biotech, Inc. | |
| Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma | NCT04513028 | Melanoma Stage ... Melanoma Stage ... | Beta-Glucan | 18 Years - | University of Louisville | |
| Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors | NCT04675346 | Melanoma, Stage... Melanoma Stage ... Melanoma, Stage... | Questionnaire | 18 Years - 80 Years | Oxford University Hospitals NHS Trust | |
| Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment | NCT04045691 | Melanoma Stage ... Melanoma Stage ... | Encorafenib Binimetinib | 18 Years - | Pierre Fabre Pharma GmbH | |
| Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors | NCT04675346 | Melanoma, Stage... Melanoma Stage ... Melanoma, Stage... | Questionnaire | 18 Years - 80 Years | Oxford University Hospitals NHS Trust | |
| FMT to Convert Response to Immunotherapy | NCT05251389 | Melanoma Stage ... Melanoma Stage ... | Fecal microbiot... | 18 Years - | The Netherlands Cancer Institute | |
| To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma | NCT06204991 | Melanoma Stage ... Melanoma Stage ... Melanoma | ADP-TILIL7 Cyclophosphamid... Fludarabine Pho... Proleukin | 18 Years - 75 Years | Herlev Hospital | |
| A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma | NCT05370807 | Melanoma Stage ... Melanoma Stage ... | Regorafenib 40 ... Triplet therapy | 18 Years - | Universitair Ziekenhuis Brussel | |
| Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG | NCT05467137 | Melanoma, Stage... Melanoma, Stage... Melanoma Stage ... | MSOT | 18 Years - | University Medical Center Groningen | |
| Appropriate Dosing to Optimise Personalised Cancer Treatments | NCT04154163 | Melanoma Stage ... Melanoma Stage ... Ovarian Cancer Renal Cancer St... Renal Cancer St... Lung Cancer, No... | Dried blood Spo... Venous blood sa... | 18 Years - 100 Years | University of Dundee | |
| SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | NCT03161431 | Melanoma Stage ... Melanoma Stage ... | SX-682 Pembrolizumab | 18 Years - | Syntrix Biosystems, Inc. | |
| Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease | NCT04330430 | Melanoma Stage ... Melanoma Stage ... | T-VEC | 18 Years - | The Netherlands Cancer Institute | |
| Versatile Ampification Single-Molecule Detection in Liquid Biopsy | NCT05940311 | Liquid Biopsy Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... BRAF V600E | Affinity Mediat... | 18 Years - | Regina Elena Cancer Institute | |
| Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | NCT04013854 | Melanoma Stage ... Melanoma | nivolumab Ipilimumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | NCT04455503 | Melanoma Stage ... Melanoma Stage ... | EVX-02A EVX-02B EVX-02A OR EVX-... | 18 Years - | Evaxion Biotech A/S | |
| Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | NCT03161756 | Melanoma Stage ... Melanoma Stage ... Melanoma | Denosumab Nivolumab Ipilimumab | 18 Years - | Melanoma and Skin Cancer Trials Limited | |
| A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma | NCT05751928 | Melanoma Stage ... Melanoma (Skin) | BCD-217 anti-PD1 Excision of the... Regional lympha... | 18 Years - | Biocad | |
| Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma | NCT04139902 | Melanoma Stage ... Melanoma Stage ... | Dostarlimab (TS... Dostarlimab (TS... | 18 Years - | University of Pittsburgh | |
| Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment | NCT04045691 | Melanoma Stage ... Melanoma Stage ... | Encorafenib Binimetinib | 18 Years - | Pierre Fabre Pharma GmbH | |
| FMT to Convert Response to Immunotherapy | NCT05251389 | Melanoma Stage ... Melanoma Stage ... | Fecal microbiot... | 18 Years - | The Netherlands Cancer Institute | |
| A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma | NCT05751928 | Melanoma Stage ... Melanoma (Skin) | BCD-217 anti-PD1 Excision of the... Regional lympha... | 18 Years - | Biocad | |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | NCT04410445 | Melanoma Melanoma Stage ... Melanoma Stage ... Melanoma (Skin) | Bempegaldesleuk... Nivolumab | 12 Years - | Nektar Therapeutics | |
| Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma | NCT04526899 | Melanoma Stage ... Melanoma Stage ... Unresectable Me... | BNT111 Cemiplimab | 18 Years - | BioNTech SE | |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma | NCT05732805 | Melanoma Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... Melanoma Unrese... Melanoma Metast... Melanoma Advanc... | BCD-217 BCD-100 Placebo | 18 Years - | Biocad | |
| A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | NCT04007588 | Melanoma Stage ... Melanoma Stage ... | Nivolumab BMS-986205 Ipilimumab | 18 Years - | Dana-Farber Cancer Institute | |
| Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | NCT06295159 | Melanoma Stage ... Melanoma Stage ... Advanced Melano... Melanoma | Nivolumab Nivolumab + Rel... Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | NCT04013854 | Melanoma Stage ... Melanoma | nivolumab Ipilimumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | NCT04455503 | Melanoma Stage ... Melanoma Stage ... | EVX-02A EVX-02B EVX-02A OR EVX-... | 18 Years - | Evaxion Biotech A/S | |
| (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma | NCT05767879 | Melanoma Stage ... In-Transit Meta... | Encorafenib + B... | 18 Years - | Leiden University Medical Center | |
| IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | NCT04562129 | Melanoma Stage ... Melanoma Stage ... Inoperable Dise... | Interleukin-2 Ipilimumab Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE | NCT05171374 | Melanoma Stage ... Melanoma Stage ... Melanoma | Dabrafenib Trametinib | 18 Years - | MelanomaPRO, Russia | |
| Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | NCT04741997 | Melanoma Stage ... Melanoma Stage ... BRAF V600 Mutat... | Encorafenib Pil... Binimetinib Pil... Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis | NCT04305145 | Melanoma Stage ... Melanoma Stage ... Skin Cancer Sta... Skin Cancer Sta... Drug-Induced Co... Drug Toxicity Immune-related ... | Infliximab Methylprednisol... Prednisone | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
